adaptor related protein complex 5 subunit zeta 1Genealiases: KIAA0415 · SPG48 · zeta
Q-omics provides the consensus-scored AP5Z1 profile across patient tissues and cancer cell-line models. AP5Z1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AP5Z1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, AP5Z1 RNA expression shows 18,862 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where AP5Z1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AP5Z1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AP5Z1 survival associations across molecular data types. AP5Z1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AP5Z1 RNA expression–survival associations across cancer types. High AP5Z1 expression shows unfavorable associations in KIRC, KICH, LIHC, MESO, COAD and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AP5Z1 RNA expression.
This table summarizes AP5Z1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for AP5Z1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AP5Z1 shows higher tumor expression in HNSC, KIRP, KIRC, COAD, LIHC and BLCA. The HNSC box plot shows higher AP5Z1 RNA expression in tumor versus normal tissue (log2 FC = +1.358, t-test p < 0.001).
This table shows molecular features associated with AP5Z1 in patient tissues and cancer cell lines. In patient samples, AP5Z1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, AP5Z1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
